Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: BARRY ALLEN who wrote (569)	5/4/1998 7:25:00 PM
From: Brian Malloy	Read Replies (1) \| Respond to of 2135

I have known of ADVR for many years and I would highly suggest that people do an extensive amount of due diligence before investing in this company. This drug is always undergoing one type of trial or another, generally outside of the US. Whatever the hot topic is, they try to make it fit. Drug has been around since the 60's and maybe earlier. It was dropped by a major pharmacetical company that made it and picked up by what is now ADVR. All investors should proceed with extreme caution. Barry's recent post on ADVR is informative: "ENMD.....What a play for a company that is 12-18 months away from phaseI clinicals! biz.yahoo.com Poor ADVR.....years ahead of ENMD and grossly undervalued! " The potential of ENMD and angiostatins is very very promising, the reality of ADVR is quite the opposite.

To: BARRY ALLEN who wrote (569)	5/4/1998 7:57:00 PM
From: Jeff Briley	Respond to of 2135

BLSI CEO on CNBC at 9:15 E.S.T. tomorrow. In BLSI Press Release today, the CEO stated that, "We do have a technology called Troponin that works in a similar manner to Entremed's technology." He also stated, "We hope to file an IND (investigational new drug application) during the second half of the year seeking permission to go into clinical trials." ENMD BLSI Market Cap(M) 143.7 28.62 Shares Oustanding(M) 12.23 12.72 Float (M) 5.90 10.20 3 month Avg. Daily Vol.(M) .06 .06 Book Value 3.60 1.47 Sales/Share .39 .01 Cash/Share 3.76 1.27 Earnings/Share -.53 -.68